Sanofi (SNY)
After hours:
| Previous close | 53.10 |
| Open | 52.67 |
| Bid | 52.38 x 700 |
| Ask | 52.44 x 700 |
| Day's range | 52.37 - 52.85 |
| 52-week range | 42.63 - 55.72 |
| Volume | |
| Avg. volume | 2,366,234 |
| Market cap | 131.343B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 28.79 |
| EPS (TTM) | 1.82 |
| Earnings date | 25 Oct 2024 |
| Forward dividend & yield | 2.04 (3.98%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | 59.89 |
ZacksPharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
Investor's Business DailyAstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.
GlobeNewswirePress Release: Online availability of Sanofi’s half-year financial report for 2024
Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K. This document may be found on the company’s corporate website: www.sanofi.com and downloaded from the “Investors” page, under the
